Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD3 | Q15059 | 16/20 | 0.43 |
| ▸ | BRD4 | O60885 | 15/20 | 0.43 |
| ▸ | BRD2 | P25440 | 12/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740574 | 0.86 | BRD4 (0.43) | BRD3BRD4BRD2CREBBPMEN1 | |
| SCHEMBL16740431 | 0.84 | BRD4 (0.44) | BRD3BRD4BRD2CREBBP | |
| SCHEMBL16740457 | 0.83 | BRD3 (0.41) | BRD3BRD4BRD2CREBBPMEN1 | |
| SCHEMBL16740438 | 0.82 | BRD4 (0.46) | BRD3BRD4BRD2CREBBPKEAP1 | |
| SCHEMBL16740478 | 0.81 | BRD3 (0.40) | BRD3BRD4BRD2CREBBP | |
| SCHEMBL16268422 | 0.79 | CREBBP (0.35) | BRD3BRD4BRD2CREBBPKEAP1 | |
| SCHEMBL16740529 | 0.77 | BRD3 (0.46) | BRD3BRD4BRD2CREBBPMEN1 | |
| SCHEMBL16268718 | 0.76 | BRD4 (0.33) | BRD3BRD4BRD2CREBBPKEAP1 | |
| SCHEMBL16740427 | 0.76 | BRD4 (0.45) | BRD3BRD4BRD2CREBBP | |
| SCHEMBL16740564 | 0.74 | BRD4 (0.39) | BRD3BRD4BRD2CREBBPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550796-B2 | Pyrrolopyrrolone derivatives and their use as BET inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3071571-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Novartis AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015075665-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | NOVARTIS AG (CH) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | BET1, PHKB, TMPO | BRD3 12/4885BRD4 5/4885BRD2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.